Erste Asset Management GmbH lowered its stake in Astrazeneca Plc (NYSE:AZN – Free Report) by 1.0% during the 4th quarter, HoldingsChannel reports. The firm owned 972,748 shares of the company’s stock after selling 9,900 shares during the period. Astrazeneca comprises 1.4% of Erste Asset Management GmbH’s holdings, making the stock its 13th largest position. Erste Asset Management GmbH’s holdings in Astrazeneca were worth $170,717,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lloyd Advisory Services LLC. purchased a new stake in Astrazeneca in the fourth quarter worth approximately $35,000. Basepoint Wealth LLC purchased a new stake in Astrazeneca in the fourth quarter worth approximately $44,000. Nemes Rush Group LLC boosted its holdings in Astrazeneca by 162.1% in the fourth quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock worth $47,000 after purchasing an additional 167 shares during the last quarter. Bangor Savings Bank boosted its holdings in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC purchased a new stake in Astrazeneca in the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.
Analyst Ratings Changes
AZN has been the topic of several research reports. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Finally, UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Stock Up 0.1%
AZN opened at $186.06 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a market capitalization of $288.57 billion, a PE ratio of 27.94, a PEG ratio of 1.59 and a beta of 0.25. The firm’s 50 day simple moving average is $190.84 and its two-hundred day simple moving average is $185.34.
Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts forecast that Astrazeneca Plc will post 9.52 EPS for the current year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
